94 studies found for:    Heart Block | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
Condition: Coronary Artery Bypass
Interventions: Drug: Prasugrel;   Drug: Placebo
22 Recruiting Galectin-3 Blockade in Patients With High Blood Pressure
Condition: Hypertension
Intervention: Dietary Supplement: Modified Citrus Pectin (MCP)
23 Recruiting Effect of Fasting on the Asthma Inflammasome
Condition: Asthma
Intervention:
24 Recruiting Longitudinal Observational Study of Severe Asthma
Condition: Asthma
Intervention:
25 Recruiting Randomized Controlled Trial of Group Prevention Coaching
Condition: Cardiovascular Disease
Intervention: Behavioral: Problem Solving
26 Recruiting Randomized Endo-Vein Graft Prospective
Condition: Coronary Artery Bypass Grafting
Intervention: Procedure: Vein Harvesting Procedures
27 Recruiting Antibody Treatment for Advanced Celiac Disease
Conditions: Celiac Disease;   Celiac Sprue;   Gluten Enteropathy;   Gluten-Sensitive Enteropathy
Intervention: Biological: Hu-Mik- Beta-1
28 Recruiting Lidocaine For Neuroprotection During Cardiac Surgery
Condition: Cognitive Decline
Interventions: Drug: Lidocaine;   Drug: Placebo
29 Not yet recruiting Reevaluation Of Systemic Early Neuromuscular Blockade
Condition: Acute Respiratory Distress Syndrome
Intervention: Drug: cisastracurium besylate
30 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
31 Recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions: Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
32 Recruiting Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access
Condition: Aortic Valve Stenosis
Intervention: Procedure: CA-TAVR
33 Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Drug: pemetrexed disodium
34 Recruiting Natural History of Sickle Cell Disease and Other Hemolytic Disorders
Conditions: Hemoglobin SC Disease;   Hematologic Diseases;   Sickle Cell Anemia;   Hemolytic Anemia
Intervention:
35 Recruiting Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Condition: Healthy Subjects
Intervention:
36 Recruiting PAHTCH (Carvedilol)
Condition: Pulmonary Hypertension
Interventions: Drug: Carvedilol;   Drug: Carvedilol placebo
37 Recruiting Validation of Coronary Calcium Subtraction to Improve Diagnostic Accuracy of Coronary CT Angiography
Condition: Coronary Artery Disease
Intervention:
38 Recruiting Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Interventions: Drug: albuterol inhaler;   Procedure: PFT;   Drug: albuterol nebulizer
39 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
40 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years